|
-
 Click for R&D Project Inquiry
What is an aptamer?
Aptamers (synthetic antibodies) are (stable) single-stranded DNA, RNA, or peptide molecules capable of binding to its target antigen with high affinity and specificity. Aptamers (synthetic antibodies) have been developed against a wide variety of targets ranging from small organics to large proteins.
Benefits
* Manufacturing costs and time are all lower compared to that of monoclonal antibody production.
* Once the aptamer (nucleic acid) sequence is known, the aptamer (synthetic antibody) can be produced on the fly using an oligo synthesizer to meet ones immediate needs.
* Easy to label with reporters, enzymes, or fluorescent tags.
* Cost Benefit Comparison of Antibodies and Aptamers. PDF (97.3KB) 
Aptamers Against Virtually Any Target!
Proteins.
Organics.
Toxins.
Brochures:
- Diagnostic and Biomarker Detection. PDF (215KB)
- Forget Antibodies. Use Aptamers. PDF (213KB)
-
Click for R&D Project Inquiry
Using the current antibody method; for every drug that makes it to market, hundreds of promising candidates that worked in-vitro (on the lab bench) fail during animal ADMET studies (absorption, distribution, metabolism, excretion, and toxicity). From lab bench to pharmacy shelves it takes from seven to fifteen years and costs $4B with an average failure rate of 80%. Half of this time and approximately 70% of all associated biopharmaceutical R&D costs are spent on in-vitro development.
Because aptamers (synthetic antibodies) are an in-vivo (directly tested in the animal model) approach, they avoid the majority of the bench testing, saving several years and approximately 35% of the R&D cost. The unique chemistry of aptamers, unlike other forms of drugs currently used, permits the natural selection of drug candidates in whole animal models, bypassing the test tube entirely. By using an animal model with the disease state of interest, Aptagen need not possess specific knowledge of the pathology or disease condition in question. As an added benefit, because this approach reduces the false starts, there are actually fewer animals needed for drug evaluation.
Contact Us to schedule a webinar.
Brochures:
- Perspective - Aptamers as Drugs. PDF (103KB)
- Aptabody Narrative. PDF (136KB)
- Aptagen Selection Data. PDF (331KB)
- Example Progress Report. PDF (197KB)
-
Click for R&D Project Inquiry
Aptagen's rapid fast-track approach to drug discovery bypasses the 'test tube' in pre-clinical development, taking it one step closer to human clinical trials.
In Vitro Assays -----> In Vivo Studies ------> Clinical Trials
The Problem: Drug candidates that prove positive in "test tube" (or in vitro) assays may face substantial problems when tested in animals, a necessary prerequisite before human clinical trials. These problems include absorption, distribution, metabolism, excretion, and toxicity.
The Solution: Aptagen's technique, involving molecules called aptabodies™ (patent pending), overcomes the limitation of the traditional pharmaceutical drug discovery process. The unique chemistry of aptabodies™, unlike other forms of drugs currently used, permits the selection of drug candidates in whole animal models, bypassing the "test tubes" entirely, and taking drug development one step closer to human clinical trials. By using an animal model with the disease state of interest, specific knowledge of the pathology or disease condition is not needed. An added benefit is the significant reduction in the number of animals needed for drug evaluation before entering into human clinical trials.
BENEFITS: overcome delivery issues * * identify unknown biomarkers * * tailor PK/PD properties * * rescue failed drug candidates from targeting/specificity issues
Spending too much time and capital on the trial-and-error approach to Drug Discovery?
On average, only one in a thousand drug candidates make it to human clinical trials. The cost and time associated with the traditional method of drug development is expensive and quite slow (7 to 15 years and almost $1 Billion). However, Aptagen's technology significantly reduces the unpredictability, cost, and time for drug discovery and development.
Over a century ago, Paul Ehrlich described the ideal drug, famously known as an 'agic bullet,' in which it specifically targets the disease site and would not harm healthy tissue. However, finding these magic bullets with drug-like properties involves a trial and error approach and is extremely slow. Aptagen has developed the concept of a ‘replicating magic bullet’ called an aptabody™. The aptabody™ technology has a shorter development time compared to traditional methods of drug development, and can be used to increase the specificity and improve delivery of existing drug compounds resulting in the next generation of pharmaceuticals with improved pharmacodynamics and pharmacokinetics.
Brochures:
- Aptagen Drug Development Services. PDF (2.07MB)
- Cost-Benefit Chart. PDF (734KB)
Contact us for more information on how we can solve your drug pipeline needs.
-
Click for R&D Project Inquiry
|
What is an aptabody™? A functionalized-enhanced aptamer or chemical antibody (patent pending) forming a supramolecular structure that may exhibit unique and interersting properties for industrial applications, diagnostics, therapeutics and drug discovery.
Conventional antibodies have a chemical alphabet of the naturally occurring amino acids. Aptabodies™, by definition, have a chemical alphabet of all amino acids, fatty acids, sugars, as well as synthetic compounds, cofactors, metal ions, etc...
|
Can aptabodies represent a class of artificial enzymes, biomaterials, and nanomaterials? Contact Us.
 Terms & Conditions
If a quote from another source is less than ours, send us the documentation, and Aptagen will match the competitor price.
1) Oligos are either PAGE or HPLC purified and mass spec verified.
2) Typical delivery is 5 to 10 business days.
** Oligonucleotide length, sequence, GC Content, coupling efficiencies, and purification can affect the final product yield.
Final Price will be decreased accordingly if delivered amount is less than expected. Final amounts greater than expected will be delivered at no extra cost.
SALES:
Orders may be placed by telephone, e-mail, or web-order submission at:
Aptagen, LLC
250 North Main Street, Jacobus, PA 17407, USA
(717) 278-2436
mailbox@aptagen.com
www.aptagen.com
There is no minimum order requirement. Our office hours are 8:00 a.m. to 6:00 p.m. EST, Monday through Friday. During this time, an Aptagen representative should be available to take your order and answer any questions you may have regarding our products or aptamers/oligo synthesis in general. Messages may be left on voice mail at any other time.
DISCOUNTS:
Orders made through www.aptagen.com may be subject to promotional, multi-order, or special discounts.
TERMS AND CONDITIONS OF SALE:
Delivery will originate from South-Central Pennsylvania and shipping times may vary coast-to-coast. Delivery within the Continental United States is FREE of charge and will be prepaid by Aptagen, LLC. Delivery to Alaska, Hawaii, or Outlying U.S. Protectorates will be subject to an additional charge and will be prepaid by Aptagen, LLC. Delivery to all International customers (including all import, customs fees, and applicable taxes), will be the responsibility of the Customer and must be paid by the Customer.
For all Orders less than $2,000: Aptagen will begin synthesis the day an order is received and will issue an invoice to the customer upon shipment of the Product which shall be due upon receipt of the Product by the Customer.
For all Orders greater than $2,000 but not more than $4,000: Aptagen will issue an invoice to the Customer prior to starting any synthesis for 20% of the total amount due; synthesis will begin once payment of this invoice has been received. Aptagen will issue an invoice to the Customer for the remaining 80% of the total amount due upon shipment of the Product which shall be due upon receipt of the Product by the Customer.
For all Orders greater than $4,000: Aptagen will issue an invoice to the Customer prior to starting any synthesis for 40% of the total amount due; synthesis will begin once payment of this invoice has been received. Aptagen will issue an invoice to the Customer for the remaining 60% of the total amount due upon shipment of the Product which shall be due upon receipt of the Product by the Customer.
Amounts not paid when due may incur an interest charge of twelve (12) percent per month until fully paid. Customer shall be responsible for any and all taxes on Products sold to it, including state and local sales and use taxes. We reserve the right to require payment in advance before shipping any materials ordeAptagen warrants that each product conforms to the specifications for such product. If the Customer notifies Aptagen within thirty (30) days of its receipt of a product that the product does not conform to the specifications, Aptagen will, at its option, replace the product or return the purchase price paid by Customer, less any cost of materials utilized in production of the Product. No replacement or refund will be made if the Customer does not notify Aptagen of a non-conforming product within said thirty (30) day period.
Aptagen makes no other express or implied warranty with respect to the products. Aptagen disclaims all implied warranties, including the warranties of merchantability and fitness for a particular purpose. Aptagen¡¦s liability for breach of warranty is limited to refund of purchase price paid, less any cost of materials utilized in production of the Product. In no event shall Aptagen be liable for lost profits, loss of goodwill or any incidental, special or consequential damages even if advised of the possibility of same.
It is the sole responsibility of the Customer (Buyer) to determine the suitability of any of the listed products for any specific purpose. Responsibility for accidents arising from the handling and use of the listed products rests solely with the Buyer. All of the products should be handled only by trained personnel who are aware of the potential hazards and have ready access to suitable safety equipment. All products supplied are primarily for research and development purposes and Aptagen products are not intended for use in foods or drugs, or for any commercial purpose.
PATENT/INTELLECTUAL PROPERTY:
As a research and development company, Aptagen realizes the desirability of patents to cover original research and it is our policy to avoid infringing upon any approved patents. Should any original research be performed, it shall be under the sole ownership of Aptagen, unless expressly addressed under legal documentation or agreement elsewhere. Aptagen reserves the right to withdraw or adjust pricing of any product at any time as patents are approved, issued, and/or discovered.
Aptagen shall not be liable for breach of any existing patent or intellectual property rights in association with any Product delivered. Aptagen performs the service of producing a Product requested by the Customer, intended for research and development purposes only. The Customer will not hold Aptagen responsible for any rights which are unknowingly infringed upon as a consequence of the production of or the commercialization of any Product contained here within.
The information provided in the Aptamer Catalog™ was obtained from the published literature. Aptagen's products are synthesized oligonucleotides based on RNA or DNA sequences. It is the responsibility of the end-user to abide by any IP rights associated with the use of any DNA or RNA oligos regardless of the source of material.
Call us to help solve your application needs | Phone: 717-APTAGEN | 717-278-2436
Email: mailbox@aptagen.com
|